akesogen.com

— Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, today announced the acquisition of AKESOgen, an industry-leading commercial laboratory facility and provider of genomics and clinical trial precision medicine services based in Atlanta. AKESOgen’s breadth of capabilities strategically complement our own, and we look forward to bringing the power of data and artificial intelligence to healthcare and advancing the field of precision medicine together. With the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make real-time, data-driven decisions to deliver personalized patient care and in parallel facilitate discovery, development and delivery of optimized therapeutic options for patients through distinctive solution sets. About AKESOgen AKESOgen is an integrated CLIA-compliant and CAP-accredited genomics, genetics and bio-banking company that works with the pharmaceutical, biotechnology, clinical, academic, and government sectors for clinical trials, diagnostic clinical testing, and research.

Dr. Bouzyk was invited by the College of American Pathologists to be on the faculty and a speaker for this International Education Program where participants came from various laboratories in South America including Brazil and Argentina. Dr. Leonas Bekeris (CAP Regional Commissioner, South America and Mexico), Denise Driscoll (Senior Director, Accreditation & Regulatory Affairs, CAP), Dr. Bharati Jhaveri (Governor, College of American Pathologists, Chair Council on Accreditation, International Deputy Regional Commissioner), Dr. Mark Bouzyk (CSO, AKESOgen) – the CAP faculty for the event – and Dr. Edgar Gil Rizzatti (Medical and Technical Executive Director (GrupoFleury, Brazil) – who hosted the event.

(AIM: RENX), a developer of artificial intelligence-enabled diagnostics for kidney disease, today announced the completion of a joint venture partnership agreement with AKESOgen, an industry-leading commercial laboratory facility and provider of clinical trial precision medicine services located in Atlanta, Georgia. RENX AI Labs will help support the programs of pharmaceutical companies by applying AI-enabled diagnostics, beginning with KidneyIntelX, which is currently undergoing clinical validation, to improve patient characterization3 and enrich targeting of patients for drug clinical trials for renal disease. In the United States alone, over 40 million people are classified as having chronic kidney disease, with nearly 50 percent of individuals with advanced (Stage IV) disease unaware of the severity of their reduced kidney function. AKESOgen is an integrated Clinical Laboratory Improvement Amendments (CLIA) compliant and the College of American Pathologists (CAP) accredited genomics, genetics and bio-banking company that services the pharmaceutical, biotechnology, clinical, academic, and government sectors for clinical trials, diagnostic clinical testing, and research.

, Inc. is a recipient of a $5,000 grant in the annual Atlanta Metro Export Challenge (Atlanta MEC), a grant program designed to engage small- and medium-sized businesses in metro Atlanta in the development of international sales plans. Over the last two years, the program has given out more than $400,000 to metro Atlanta companies thanks to the generous sponsorship of JPMorgan Chase & Co, which again contributed $100,000 to this year’s program. JPMorgan Chase is pleased to help metro Atlanta businesses grow in the international economy,” said David Balos, head of JPMorgan Chase’s Middle Market Banking group in Georgia. AKESOgen is an integrated Clinical Laboratory Improvement Amendments (CLIA) compliant and the College of American Pathologists (CAP) accredited genomics, genetics and bio-banking company that services the pharmaceutical, biotechnology, clinical, academic, and government sectors for clinical trials, diagnostic clinical testing, and research.